The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biSpecific MAbs market report forecasts the biSpecific MAbs market size to grow to XX Billion by 2027, with a CAGR (compound annual growth rate) of more than 18%.

Learn More On The BiSpecific MAbS Market Report 2023 – https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

BiSpecific MAbS Market Size Forecast
The global biSpecific MAbs market is expected to grow from $5.13 billion in 2022 to $6.72 billion in 2023 at a compound annual growth rate (CAGR) of 31.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bi-specific MAbs market is expected to grow from $13.16 billion in 2027 at a CAGR of 18.3%.

North America held the largest biSpecific MAbs market share.

Key BiSpecific MAbS Market Driver ­– Increase In The Prevalence Of Cancer And Other Chronic Diseases
For instance, in February 2022, according to the World Health Organization, a Switzerland-based international public health agency of the United Nations, cancer will be the leading cause of deaths across the globe, causing almost 10 million fatalities in 2020, or almost one in every six deaths. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. Additionally, in October 2022, according to the Centers for Disease Control and Prevention, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.

Request for A Sample Of The Global BiSpecific MAbS Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Key BiSpecific MAbS Market Trend – Strategic Initiatives
Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.

BiSpecific MAbS Market Segment
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Other Indications
4) By End Use: Hospitals, Research Institutes, Other End-Users

BiSpecific MAbS Market Major Players and Strategies
Major players in the biSpecific MAbs market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott.

In August 2020, AbCellera, a biotechnology firm based in Canada, completed the acquisition of the OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera’s existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics.

The BiSpecific MAbS Global Market Report 2023 covers regional data on biSpecific MAbs market size, biSpecific MAbs market trends and drivers, opportunities, strategies, and biSpecific MAbs market competitor analysis. The countries covered in the biSpecific MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy.

View More Reports Related To The BiSpecific MAbS Market –
Monoclonal Antibodies MAbS Global Market Report 2023
Conjugated Monoclonal Antibodies Global Market Report 2023
Biosimilar Hormones Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: